TSCAN THERAPEUTICS INC

TCRXNASDAQ

🏆 #3598 by market capUS Equity

$0.77▼ $0.00 (−0.42%)

Market closed · at close

1h—

24h▼ 0.4%

7d▼ 0.8%

14d▲ 4.0%

30d▼ 24.5%

1y▼ 53.5%

🏦Market Cap

$51M

Small Cap

📈Revenue Growth (YoY)

+106.7%

High Growth

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

5.5x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $0.76 – $0.79
52-Week Range: $0.72 – $2.57
Volume: $3.25B
Avg Volume: $3.73B
Shares Outstanding: 65.3M
Next Earnings: Aug 30, 2026

Fundamentals Snapshot

Annual Revenue: $10M
Last Q Revenue: $982,000
P/E Ratio: —
P/S Ratio: 5.5x
EPS (TTM): $-0.96
Dividend Yield: —

Why Investors Own TCRX

✓High-growth profile — revenue up +17.7% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$10M▲ +23.5% YoY

Gross Margin (TTM)

40.3%▲ +3.1% YoY

Operating Income (TTM)

$2M▲ +23.5% YoY

Free Cash Flow (TTM)

$1M▲ +23.5% YoY

About TSCAN THERAPEUTICS INC

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

🦦